Haoyuan Pharmaceutical: Su Xin Fund plans to reduce its stake in the company by no more than 0.26%.

Hao Yuan Pharmaceuticals announced on December 21st that the shareholder Su Min Investment Junxin Industrial Upgrading and Technological Innovation Equity Investment Partnership plans to reduce its holdings through centralized bidding by no more than 546,400 shares, representing no more than 0.26% of the company's current total share capital.